Please check your internet connection and try again.
# Tradjenta (linagliptin)
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which leads to increased insulin release and decreased glucagon levels.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
The recommended dose is 5 mg orally once daily. It can be taken with or without food.
## Pediatric Dosing
Dosing for pediatric patients has not been established.
## Dose Adjustments
No dose adjustment is required for patients with renal or hepatic impairment.
## Contraindications
Hypersensitivity to linagliptin or any excipient in the formulation.
## Adverse Effects
Common adverse effects include nasopharyngitis and diarrhea. Rare but serious adverse effects include hypoglycemia (especially when used with sulfonylureas or insulin), pancreatitis, angioedema, and severe arthralgia.
## Key Drug Interactions
* **Sulfonylureas and Insulin:** Increased risk of hypoglycemia. Dose reduction of the sulfonylurea or insulin may be necessary.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, fenobarbital):** May decrease linagliptin exposure and efficacy. Coadministration is not recommended.
## Monitoring
* **Glycemic control:** Monitor HbA1c regularly.
* **Pancreatitis:** Assess for persistent severe abdominal pain, which may indicate pancreatitis.
* **Hypersensitivity reactions:** Monitor for signs and symptoms of angioedema or allergic reactions.
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors as it is primarily eliminated via the hepatobiliary system, thus not requiring dose adjustments in renal impairment.
* Consider the risk of hypoglycemia, particularly when coadministered with insulin secretagogues (e.g., sulfonylureas) or insulin.
***
*Disclaimer: This information is intended for healthcare professionals. Always verify current prescribing information, dosage guidelines, and contraindications with the most recent product labeling and relevant clinical literature before dispensing or administering any medication.*
